Nuzenio

Novartis Novartis

Novartis Novartis news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 11 publisher sources 100/100 entity strength

Latest news

Dr Reddy’s to discontinue marketing of Novartis in-licensed brands from October - ET PharmaET Pharma · Mon, 10 Aug 2026 02:22:44 GMTSamsung Bioepis battles Janssen, Pfizer, Novartis in global biosimilar suits - CHOSUNBIZ - ChosunbizChosunbiz · Mon, 10 Aug 2026 00:42:00 GMTNovartis (SWX:NOVN) FDA Approval Puts Pluvicto Value Story Back In Focus - simplywall.stsimplywall.st · Sun, 09 Aug 2026 18:33:36 GMTNovartis Appoints Dima Sweiss as Country President – Levant - hrtoday.inhrtoday.in · Sat, 08 Aug 2026 17:49:48 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - NovartisNovartis · Sat, 08 Aug 2026 12:24:46 GMTNovartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next - NovartisNovartis · Sat, 08 Aug 2026 12:10:20 GMTDr Reddy's Terminates Novartis India Agreement After Ownership Change - NDTV ProfitNDTV Profit · Sat, 08 Aug 2026 05:35:44 GMTNovartis Enrolled First Participant in Phase 3 PRESERVE Clinical Trial for Experimental PSP-RS Treatment - AFTD - The Association for Frontotemporal DegenerationAFTD - The Association for Frontotemporal Degeneration · Wed, 05 Aug 2026 13:00:45 GMT

Timeline

Mon, 10 Aug 2026 02:22:44 GMTDr Reddy’s to discontinue marketing of Novartis in-licensed brands from October - ET Pharma
Mon, 10 Aug 2026 00:42:00 GMTSamsung Bioepis battles Janssen, Pfizer, Novartis in global biosimilar suits - CHOSUNBIZ - Chosunbiz
Sun, 09 Aug 2026 18:33:36 GMTNovartis (SWX:NOVN) FDA Approval Puts Pluvicto Value Story Back In Focus - simplywall.st
Sat, 08 Aug 2026 17:49:48 GMTNovartis Appoints Dima Sweiss as Country President – Levant - hrtoday.in
Sat, 08 Aug 2026 12:24:46 GMTFDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease - Novartis
Sat, 08 Aug 2026 12:10:20 GMTNovartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next - Novartis

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Novartis Novartis.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

11 distinct publisher/source names are currently connected to this entity page.